Highly efficient vaccines for Bluetongue virus and a related Orbivirus based on reverse genetics. (2020)
Attributed to:
Realising the potential of a genetically engineered and uniquely cross protective vaccine for Bluetongue disease
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.coviro.2020.05.003
PubMed Identifier: 32610251
Publication URI: http://europepmc.org/abstract/MED/32610251
Type: Journal Article/Review
Volume: 44
Parent Publication: Current opinion in virology
ISSN: 1879-6257